Abstract Germline mutations in the BRCA1/2 genes account for the majority of hereditary breast ovarian cancer (HBOC). Identification of causal mutations may have significant impact on clinical management of such families. Despite high mutation detection rate, many HBOC cases remain without identified cause. These cases warrant use of several analysis methods, such as those for large genomic rearrangements and DNA copy number changes, or analysis other genes, shown to be associated with increased HBOC risk. We assessed 585 Slovak HBOC for the presence of mutations in BRCA genes. Sequencing revealed mutations in 100 families, representing 17.1% (88 and 12% of mutations were located in BRCA1 and BRCA2, respectively). Four of the mutations, c.80?4del4, c.1938_1947del10 and c.1166delG in BRCA1 and c.6589delA in BRCA2 gene have been described only in Slovak population. Using MLPA analysis, we detected two large genomic rearrangements in three families, a deletion of exons 21 and 22, and a rare deletion of a whole BRCA1 gene. Twenty-seven different variants of uncertain clinical effect (four novel) and 14 distinct SNP BRCA1 haplotypes were detected. Their potential effect was considered using the prediction software packages Align-GVGD, Pmut and Polyphen. We observed that the best clinical criterion for the initiation of BRCA1 analysis is the presence of breast cancer at 40 years of age in the association with the presence of ovarian cancer diagnosed around the age of 50. Conversely, the best clinical criterion for starting with BRCA2 analysis is the presence of breast cancer diagnosed in older age (above 50), or the presence of breast cancer in conjunction with carcinomas at different sites e.g., prostate, colorectum, ovary and uterus. Finally we have seen that the analyses of other HBOC risk gene TP53 and specific mutation in CHEK2*c.1100delC in Slovak HBOC families were not efficient since no mutations were found in these genes.
Introduction
Each year, approximately 2,000 of newly diagnosed breast and 450 of ovarian cancer cases appear in Slovakia. The average risk of breast cancer in general Slovak population of women is 4-5% and of ovarian cancer 2% [1] . About 5% of breast or ovarian carcinomas show Mendelian, monogenic, autosomal-dominant inheritance represented by hereditary breast and ovarian cancer syndrome (HBOC), for which two major associated genes (BRCA1, BRCA2) have been identified [2] .
The BRCA1 gene was localized on chromosome 17q21. It contains 24 exons and encodes a 208-kDa protein composed of 1863 amino acids [3] . The second breast cancer susceptibility gene, the BRCA2 was localized to chromosome 13q12.3 and consists of 27 exons encoding a 380-kDa protein composed of 3418 amino acids [4] . The BRCA proteins are mainly involved in the repair of DNA doublestrand breaks (DSB) and in homologous recombination (HR).
About 85% of causal germline alterations in the BRCA1/ 2 are frame-shift or nonsense mutations, which lead to the truncation of the protein. The particular mutations differ in distribution depending on ethnicity and geographic location. Some authors believe that missense variants and single nucleotide polymorphisms (SNPs) in high penetrance genes may represent additional HBOC risk factors. Even haplotypes may play a more important role than an individual SNP. BRCA1 is hypothesized to be a locus under recombination inhibition, and very few haplotypes have been described here [5] . Frosk et al. [6] in their recent study identified eight distinct haplotypes in BRCA1, mostly derivates of two main lineages. In BRCA2, 17 distinct haplotypes were reported, indicating more complex polymorphic pattern in this gene.
The structure of BRCA1 gene exhibiting high density (42%) of intragenic Alu repeated regions [7] together with the existence of BRCA1 pseudogene located 30 kb upstream of BRCA1 is increasing the likelihood of formation of the large genomic rearrangements (LGRs) by homologous recombination. The proportion of LGRs amongst the BRCA1 mutations in HBOC families seems to be population-dependent, varying from 2.1% in a series of Spanish breast/ovarian high-risk families [8] to 36% in the Dutch patients [9] .
Some authors refuse the so-called polygenic model for HBOC, in which the risk of breast/ovarian cancer is not influenced by only single high penetrance gene, but rather by a cumulative effect of the variations of several genes with moderate risk. Generally, the products of HBOC moderate risk genes cooperate with BRCA proteins through participation in common protein complexes and intracellular processes, such as DNA repair, transcription, cell cycle control (e.g., ATM, ATR, CHEK2, STK11/LBK1, p53, RAD50, RAD51, BARD1, BAP1, BACH1, CtIP, HDAC1/2, MSH2/6, MLH1, PCNA, PTEN, RNA polymerase II and others) [10] .
Our study was primarily focused on the evidence (analysis) of genomic germline mutations in BRCA1/2 genes and other selected HBOC risk genes, such as TP53 and CHEK2*1100delC. In the second step, we aimed to improve clinical interpretation of the role of uncertain missense variants and SNP haplotypes in Slovak HBOC families.
Materials and methods

Samples and families
All analysed individuals signed informed consent and were referred for HBOC genetic analysis on the basis of family history of breast/ovarian cancer. All tested families were classified into the groups A and B due to their family history and each group was discriminated into the four subgroups according to the number of affected cases and the age at diagnosis ( Table 1) . The analysed families and data were collected since 2002 if one of these indication criteria occurred within the family history:
(1) The presence of at least two patients with diagnosed breast or ovarian cancer amongst the direct relatives and at least one case diagnosed before age of 45 (2) The presence of bilateral breast or ovarian cancer amongst the direct relatives diagnosed at any age (3) Occurence of duplex breast and ovarian cancer in at least one patient diagnosed at any age (4) The presence of sporadic breast or ovarian cancer diagnosed at age under 35 years. (5) The presence of at least one case of male breast cancer diagnosed at any age.
Genomic DNA was extracted from peripheral blood samples using QIAamp Mini Kit (Qiagen, Germany).
PCR amplification
In a primarily used approach, we analysed a whole coding region of the BRCA genes using combination of PCR amplification, SSCP analysis and direct sequencing. BRCA1 was analysed in 38 PCR fragments: 21 of them covering coding exons 2-24, with exception of exon 11. Remaining 17 fragments covered exon 11; and were amplified by the nested PCR from two large fragments (11/5F with size of 2059 bp and 11/3F of 1846 bp). BRCA2 was analysed in 52 PCR fragments, 20 covering coding exons 2-26 (exons 5 and 6 in one fragment) with exception of large exons, which were sub-divided into smaller fragments (exon 10 into 5, 11 into 20, 14 and 18 into 2 each, exon 27 into 3 fragments). Size of all BRCA PCR fragments varied from 162 to 450 bp. The fragments with atypical mobility or with an atypical number of bands in the SSCP analysis were further sequenced. Primer sequences used for PCR amplification were similar to those published by Friedman et al. [11] , but were mostly redesigned using OligoCalc [12] .
Each 25 ll PCR reaction consisted of following reagents: 19 PCR buffer EXT, 1.5 mM MgCl 2 , 0.2 mM dNTP mix, 0.6 U EXT polymerase (all Finnzymes), 12.5 lM of each primer and 150 ng of DNA. The PCR cycling was performed using thermal profile: 94°C/4 min, 94°C/30 s, 53-65°C/ 35-50 s, 72°C/45-80 s, 72°C/7 min, 4°C/pause, for 35-45 cycles. In the nested PCR, 209 dilution of large PCR fragments was prepared, and a 3 ll aliquot was used in the reamplification of sub-fragments.
Fragment analysis
Fragment analysis using dye labelled primers was performed for the detection of most relevant frame-shift mutations: c.5266dupC in exon 20, c.68_69delAG in exon 2 of BRCA1 gene and c.1100delC in CHEK2 gene. Primers were labelled with FAM or VIC.
Allelic discrimination
Allelic discrimination analysis using TaqMan probes was used for detection of mutation p. The MLPA kit SALSA P002B and SALSA P087 (MRCHolland) were used for BRCA1 analysis and SALSA P045B (MRC-Holland) for BRCA2 and partial CHEK2 analysis (mutation 1100delC included), according to the manufacturer's protocol.
Sequencing analysis
In a novel approach of BRCA1 analysis, the exons 3, 11, 13, 16 and 18 were directly sequenced without using any pre-screening method. Exon 11 of BRCA1 was divided into seven large fragments (347-778 bp) and all were directly sequenced. PCR amplifications for direct sequencing were performed in 25 ll PCR reaction volume, using 19 AmpliTaq Gold Mastermix, 12. Hot spot exons 5-8 of TP53 gene were also analysed using direct sequencing of two large PCR fragments using primers designed according to the same rules as described previously.
The PCR fragments were purified with ExoSAP-IT (USB Corp.) according to the manufacturer's protocol. Subsequently, the sequencing reaction was prepared using 0.29 Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems), 0.759 Sequencing Buffer (Applied Biosystems), 2 lM primer and 10-20 ng of PCR product. Sequencing PCR analysis was performed with the following thermal profile: 96°C/1 min, 96°C/10 s, 50°C/5 s, 60°C/3 min, 4°C/pause for 25 cycles. Afterwards, the samples underwent postsequencing purification via columns (Sigma-Aldrich) according to the manufacturer's protocol.
Protein prediction analysis
Potential clinical effect of variants with unknown significance (UVs) was evaluated by analyses of the severity of the amino acid changes and their conservation across species. These analyses were performed using prediction analysis web tools Align-GVGD [13] , PMut [14] and PolyPhen [15] .
Nomenclature
Identified mutations were compared with human BRCA reference sequences, at the cDNA level with NM 007294.3 and U 43746.1. In the case of intronic variations, genomic DNA reference sequences NG 005905.2 and U 94788.1 were used. The HUGO-approved systematic nomenclature, for the description of sequence variants in DNA and protein sequences published by den Dunnen and Paalman [16] was used. Exonic frame-shift and all intronic mutations were assigned at the nucleotide level, whilst exonic missense and nonsense mutations were marked at the protein level using HUGO-approved systematic nomenclature.
Novel mutations
The presence of all identified mutations, uncertain variants and polymorphisms was examined in Breast Cancer Information Core database [17] , MutDb [18], HGMD database [19] and Swiss-Prot database [20] . Variants assigned as novel were not present in any of these databases.
Results
Molecular-genetic analysis of 585 HBOC families was performed using different approaches (SSCP, fragment analysis, allelic discrimination and direct sequencing and MLPA). Within this set, we identified 100 families with the presence of clearly deleterious mutations (17.1%). Majority of these 100 families carried mutations in BRCA1 (88%), remaining 12% in BRCA2 gene. Furthermore, the analysis of TP53 exons 5-8 in 64 BRCA negative families and the mutation c.1100delC of CHEK2 gene in 159 families, did not reveal any causal mutation.
Pathogenic germline BRCA1 mutations
Pathogenic mutations in BRCA1 were detected by DNA sequencing in 14.5% (85/585) of analysed families (Table 2) . Altogether, 25 different BRCA1 mutations were identified, of which 21 caused a premature stop codone (84%), 15 were frameshifts and 6 nonsense mutations. Furthermore, 2 splice-site and 2 missense mutations were detected. The majority of mutations occurred in the largest exon 11 (54%).
The most frequently detected BRCA1 mutations were c.5266dupC in 32 families (38%); p.Cys61Gly in 14 families (17%); c.68_69delAG and c.3700_3704del5 each in 4 families (5%), and finally c.843_846del4 and c.4243delG in 3 families each (4%). Altogether, mutations identified in exons 2, 5, 11 and 20 represented 86% of all BRCA1 mutation-positive Slovak HBOC families (73 out of 85). Mutations c.1166delG, c.1938_1947del10 and c.80?4del4 were previously reported only in Slovak HBOC kindreds [21] [22] [23] .
The highest detection rate of BRCA1 causal mutations (33%) was observed in families with the presence of duplex breast and ovarian carcinoma in one patient (6 of 18), followed by 33% in the group of families with the presence of breast and ovarian cancer (25 of 75), 29% in families with the presence of bilateral ovarian cancer (2 of 7), 13% in families with the presence of bilateral breast cancer (11 of 85), 12% in families with the presence of unilateral ovarian cancer (6 of 50) and 10% in families with the presence of unilateral breast cancer only (35 of 350).
The mean age at the time of cancer diagnosis in patients positive for BRCA1 mutation was 42.7 years (range 21-75). Mean age at diagnosis in the subgroup with the unilateral breast cancer was 40.7 (range 21-66), with the bilateral breast cancer 39.7 (range 30-46), with the unilateral ovarian cancer 51.2 (range 40-75) and with the duplex breast and ovarian cancer 47.5 (49, 50, 41 and 50 years). Bilateral ovarian cancer was diagnosed only in one BRCA1 positive patient (52 years).
The presence of LGRs was analysed in 61 HBOC families negative for BRCA1/2 pathogenic small mutations. The MLPA analysis of both BRCA genes and fragments of CHEK2 gene (promoter, exon 9, exon 10/c.1100delC) was performed simultaneously. Altogether, we identified three families positive for the presence of BRCA1 gene LGRs (5%), whilst no mutation was detected in BRCA2. Two types of LGRs were present, a deletion of exons 21 and 22 and a deletion of exon 1 through 24. The breakpoints of the detected LGRs were not determined.
Pathogenic germline BRCA2 mutations
Causal BRCA2 mutations were identified in 12 out of 104 families (11.5%) ( Table 2) . Nine different BRCA2 mutations were detected, 6 frameshifts, 2 nonsense mutations and 1 missense mutation of the initial Met codon. Almost all mutations cause a premature stop codon (91%). The majority of mutations occurred in the largest exon 11 (56%). Mutation c.6589delA was previously reported only in Slovak population [23] .
The detection rate 10% of BRCA2 causal mutations was observed in families with diagnosed breast cancer only (6 of 59), 9% in families with the presence of bilateral breast cancer (2 of 22). In families with the presence of breast and ovarian cancer (4 of 14), the detection rate was determined to 29%. However, in these cases the presence of male breast cancer, prostate cancer and colorectal cancer was observed as well. No causal mutations were detected in five families with the occurrence of duplex breast and ovarian carcinoma in one patient, three families with unilateral ovarian cancer and one family with bilateral ovarian cancer. Mutation c.9098dupA was detected in family with the presence of male breast cancer.
The mean age at the time of cancer diagnosis of the BRCA2-positive patients was 46 years (33-59), while in the subgroup with the unilateral breast cancer diagnosis age was 52.7 . Two positive patients with bilateral breast cancer were diagnosed at mean age of 42.5 years (33, 52) and one patient with ovarian cancer at the age of 49 years.
BRCA1/2 variants with uncertain clinical effect
In 117 HBOC families (out of 585) we identified 19 different types of UVs in BRCA1 gene (20%). In 19 cases, UVs were reveal any association with breast/ovarian cancer. Missense UVs in the BRCA2 were mostly localized in exon 11 (71%). Prediction analysis of BRCA UVs was based on the comparison of the substituted amino acids and predicted proteins using three software packages: Align-GVGD, Pmut and Polyphen. Results of the prediction analysis are shown in Table 4 . Summarizing prediction results, variants p.Glu1346Gly, p.Ser1512Ile in BRCA1 and p.Trp2626Cys, p.Val2908Gly in BRCA2 were predicted as being most probably pathogenic in all used prediction approaches. Uncertain variants p.Arg841Trp in BRCA1 and p.Gly2274-Val in BRCA2 were predicted as possible pathogenic.
BRCA SNPs and BRCA1 haplotypes
The SNPs in BRCA1 gene are mainly localized together on one allele and thus generate the SNP haplotype. The most frequently identified BRCA1 SNPs were p.Pro871Leu detected in 277 families (47%), p.Glu1038Gly in 276 families and p.Lys1183Arg in 275 families out of 585 analysed HBOC families. Altogether, 15 different BRCA1 SNPs were identified, of which six were silent, five missense and four intronic substitutions. The silent change p.Pro1562Pro in exon 16 was detected as novel, not yet reported. Major part (40%) of detected SNPs was localized in exon 11.
The most frequently identified BRCA2 SNPs were p.His372Asn observed in 83 families (80%), c.7806-14T[C in 54 families (52%) and p.Lys1132Lys in 53 families (51%) out of 104 analysed HBOC families. Altogether, 16 different BRCA2 SNPs were detected, seven silent, six missense and two intronic substitutions and one frame-shift variant. The silent change p.Asp980Asp in exon 11 was detected as novel, not yet reported. The most of identified SNPs were situated in exon 11 (50%) and in exon 10 (19%). The haplotype consisting of the 8 SNPs: p.Ser694Ser, p.Leu771Leu, p.Pro871Leu, p.Glu1038Gly, p.Lys1183Arg in exon 11, p.Ser1436Ser in exon 13, p.Ser1613Gly in exon 16 and c.5152?66G/A behind exon 18 was detected in our set of BRCA1 analysed families as the most frequent one. The second most frequent was the wild-type haplotype without any BRCA1 SNP. The spectrum of identified assumed BRCA1 haplotypes is shown in Table 5 .
Other HBOC risk genes-TP53, CHEK2*1100delC analysis The samples from the 61 HBOC BRCA negative families were analysed for the presence of germline mutations in exons 5-8 of TP53 gene. By performing sequencing analysis, no pathogenic mutation was detected. Despite this fact, we identified six different variants: five intronic variants and one silent variant in exon 6. Silent alteration p.Arg213Arg (c.836G[A) was identified in two families. Altogether, detected variants were distributed in 40% of families (24 of 60). Analysis of the CHEK2 gene using fragment analysis and MLPA analysis was focused on the most frequently reported mutation c.1100delC in exon 10 and revealed no mutation in the 159 BRCA negative families.
Discussion
Molecular-genetic analysis of BRCA1/2 genes in 585 Slovak HBOC families carried out since 2002 revealed 100 mutation-positive families (17.1%). Eighty-five and 12 families carried pathogenic mutations in BRCA1 and BRCA2, respectively, that were detected by DNA sequencing and three families carried LGRs in BRCA1 detected by MLPA. Comparing to other studies, especially from the Central European region, e.g., to Czech population with detection rate ranging from 19.8% [24] to 29.1% [25] , the detection rate in Slovak HBOC population is lower. Several factors, such as composition of families, number of families, selection criteria or used screening techniques might contribute to this inequality between historically associated populations. The detection rate comparable to ours was reported in the Sicilian population 16% [26] , or in Spain 17.1% [27] .
The highest detection rate of BRCA1 pathogenic mutations was observed in families with the presence of both breast and ovarian cancer (33%) and in families with duplex ovarian and breast carcinoma diagnosed in one patient (33%). The lowest rate of only 10% was present in families with unilateral breast cancer. According to the reported data and also comparing with other studies [25, 26, 28, 29] , the presence of ovarian cancer in association with breast cancer serves as a potential predictive factor for BRCA1 mutation positivity and represents the strongest indication. On the other hand, the presence of bilateral ovarian (17%) or breast (13%) cancer is still stronger criterion for selection as the familiar unilateral cancer. The highest BRCA2 mutation detection rate of 29% was observed in families carrying a wide range of carcinomas (breast, ovarian, colorectal, prostate and uterus) and a male breast cancer. Exclusive presence of bilateral breast cancer (9%) and unilateral breast cancer (10%) also shown association with several mutations, however, the exclusive presence of ovarian cancer does not seem to be an indication. Mean age of the BRCA1-positive patients was 43 years, ranging from 21 to 75 years. Mean age at the time of diagnosis was higher in BRCA1-negative cases (44 years, 21-70) than in BRCA1-positive cases (40 years, . Surprisingly, the mean age of patients at ovarian cancer diagnosis in BRCA1-negative cases was 45 years (22-75), but in BRCA1 positive cases was nearly 50 years (unilateral ovarian cancer-51.2 years, duplex breast and ovarian cancer-49.2 years and bilateral ovarian cancer-52 years). This observation is indicating that the presence of BRCA1 pathogenic mutations is more likely in the patients with breast cancer at 40 years and ovarian cancer at relatively higher age of 50 years. Thus, sporadic ovarian cancer cases diagnosed at very young age (under 40 years) probably should not be indicated to BRCA analysis because their cancers may be caused by the environmental and lifestyle risk factors (smoking, contraceptives, etc.).
According to our data, the BRCA1 pathogenic mutations in Slovak HBOC population may be divided into following groups:
• Frequent mutations considered as Slavic founder:
p.Cys61Gly and c.5266dupC The most frequently found BRCA1 mutations responsible for the majority of Slovak HBOC cases are c.5266dupC in 32 families (38%); p.Cys61Gly in 14 families (17%); c.68_69delAG, c.3700_3704del5 each in 4 families (5%), and finally c.843_846del4, c.4243delG each in 3 families (4%). Altogether, these six mutations accounted for 73% of the BRCA1-positive HBOC families. Similarly high frequencies of c.5266dupC and p.Cys61Gly mutations were reported in other studies of Central European populations [24, 25, 30] which is strongly indicating that at least these two mutations are caused by founder effect.
Other pathogenic mutations (27%) identified only in one or two families fall in a group of Slovak HBOC low frequency BRCA1 mutations, though some of them were detected in neighbouring populations as well. Machackova et al. [25] identified mutations p.Cys39Arg, p.Gln563X, c.2488_2497dup10, c.3700_3704del5 and p.Gln1447X in Czech population, which is probably the closest to the Slovak population. Mutations c.4065_4068del4 and p.Arg1443X were found in Sweden [31] , p.Arg1443X in the Sicilian population [26] as well as in the French population as a founder mutation [32] . Other Slovak low frequency BRCA1 pathogenic mutations were not occuring in any European HBOC report.
All detected missense causal mutations were localized in a highly conserved structure of C 3 HC 4 RING domain of BRCA1, which has been described as Zn 2? binding site of RING domain for dimerization with BARD1 [33] . Highly conserved residues C39, H41, C61, and C64 are localized in the regions where mutations p.Cys39Arg, p.Cys61Gly were observed. The small deletion c.80?4del4 results in the skipping of exon 2 and subsequent generation of an aberrant translational start in exon 5.
Interestingly, a minimum of nonsense mutations was identified in exon 11 [21, 25, 26, 28, 29] in comparison to other types of mutations in this exon and no causal missense mutations were present in this exon due to the lack of highly conserved domain in this region. However, it can not be excluded that some of the frequently occurring missense variants with uncertain clinical significance localized mainly in exon 11 (and similarly in exon 16), might have some effect on the protein function and thus play a role in the development of HBOC phenotype.
Altogether, 9 different BRCA2 mutation types in 12 families were identified in the set of 104 HBOC families (11.5%). Generally, the most of the pathogenic mutations in this gene in our series are localized in exon 11, similar to many other reports [31, 34, 35] . Interestingly, 44% of BRCA2 pathogenic mutations detected in our cohort of patients have also been reported in Czech HBOC population [26, 36] confirming the genetic relationship of these two neighbouring populations.
It seems that LGRs do not represent frequent mutational events in Slovak HBOC families (5%). Compared to other studies, our LGR detection rate was similar to the one in Czech 5.8% [37] or German population 5.3% [38] . Deletion of exons 21-22 in BRCA1 gene was previously reported in Czech population [37] . This deletion affects the C-terminal BRCT domain of BRCA1 protein and results in the skipping of 43 amino acids from the position 1760-1802. This loss of a part of the conservative BRCT domain is suggested to have a cancer susceptibility effect. Deletion of exon 1 through 24 represents a very rare event and was previously reported in one Spain [8] and one German family [39] . Identifying the second family with the same deletion of BRCA1 allele living in the same geographical area raises the question whether these two mutations are exactly identical, what can be answered after the determination of breakpoints. Alternatively, testing of families relationship and haplotype analysis of family members may reveal wether this mutation is family specific or represents a new Slovak founder mutation.
Mutation detection rate of BRCA1/2 uncertain variants in Slovak HBOC families is relatively high, 23% (133 families), in contrast to recent studies reporting substantially lower frequencies: 6.8% in Spanish population [40] , 5.7% in Sicilian population [26] , 5.1% in Indonesian population [41] , only 1.5% in both, New Zealand and Australian populations [42] ; and 0.86% in US HBOC families [43] . A big deviation in the detection rates may reflect sensitivity of detection techniques used in the different studies. In some studies, the identification of mutations in exon 11 was based on the performance of techniques such as SSCP, PTT, DGGE, CSGE [40] or DHPLC [29, 41] . We assume that employment of direct sequencing for analysis of large exons in our study resulted into the identification of a broader spectrum of missense UVs.
However, interpretation of uncertain variants still remains problematic. Prediction of the effect of UVs in functional analysis studies and in the prediction software may generate controversial results. Complex evaluation of missense UVs should consist of the combination of several approaches based on, but not limited to cosegregation analysis of UVs with disease in a family, loss of heterozygosity in tumours, determination of the frequency of variant in unaffected controls, in silico prediction analysis, functional assays [44] . In our study, we analysed the BRCA UVs using prediction software [13] [14] [15] , next by studying the association of UVs with pathogenic mutation and number of entries in the BIC database and finally, if possible, by performing a cosegregation analyses of UVs with the disease. Taking in account the results of our examinations, we suggest that BRCA2 variants p.Gly2274Val, p.Trp2626Cys and p.Val2908Gly, and BRCA1 variants p.Glu1346Gly and p.Ser1512Ile are very likely pathogenic. Interestingly, relatively high portion of variants in BRCA2 gene are predicted as possible pathogenic (Table 4) . However, these predictions should be confirmed by the segregation analysis of oncological disease within the affected family and other type of analyses in the future.
It is believed that the explanation of discrepancy between the frequency of hereditary breast/ovarian cancer families and detected BRCA mutations may lie in a polygenic heredity with many non-BRCA moderate risk susceptibility genes, although the existence of an autosomal recessive mendelian allele cannot be excluded [45, 46] . In this sense, breast cancer represents a complex genetic disease. Moderate risk candidate genes, which presumably alter breast cancer predisposition, may be found in a variety of pathways, ranging from the detoxification of environmental carcinogens to the steroid hormone metabolism and the DNA damage repair [47] . On the other hand, we suggest that many features of BRCA genes such as promoter sequences, epigenetic changes, microRNA, uncertain variants, intronic splice variants or SNP haplotypes may represent additional factors that might seriously alter the risk of breast/ovarian cancer onset. We hypothesize that so-called 'BRCA intra-gene modifier factors' should be more investigated and may bring alternatives to polygenic models. SNP haplotypes in BRCA genes are mostly determined by the presence of a set of SNPs, which are grouped on one allele and inherited in a linkage. Haplotypes may play a more important role than individual SNPs and may alter the risk of breast/ovarian cancer. Identification of such haplotypes depends on the analysis of large number of samples to obtain sufficient amount of data. BRCA1 gene is a relatively optimal example since this gene is hypothesized to be a locus under recombination inhibition with very few haplotypes described. In fact, only one haplotype block and two major haplotypes have been shown to exist in Caucasians [5] . However, in BRCA2 gene the situation concerning haplotypes is more complex, reflecting the existence of a large number of variations [48] .
We observed the main haplotypes of BRCA1 gene in Slovak HBOC families, their homozygous or heterozygous status and we tried to interpret their possible clinical effect and/or identify a possible pathogenic haplotype. The most frequent haplotype (31.4%) seen in Slovak HBOC families consists of SNP variants: p.Ser694Ser, p.Leu771Leu, p.Pro871Leu, p.Glu1038Gly, p.Lys1183Arg in exon 11, p.Ser1436Ser in exon 13, p.Ser1613Gly in exon 16 and intronic variants c.4987-68G[A in intron 16, c.5152? 66G[A in intron 18. The presence of a set of variants on both alleles (in homozygous stage) or the presence of two different SNP haplotypes (each in heterozygous stage) may importantly alter the biological pathways dependent on the BRCA1 protein. Interestingly, the pathogenic mutation p.Cys61Gly was in all 13 cases associated with the same haplotype with uncertain variant p.Gln356Arg. The significance of this observation and our assumptions may be supported by future investigations involving more functional and segregation analyses.
Conclusions
The analysis of BRCA1 and BRCA2 genes in 585 Slovak HBOC families revealed the presence of deleterious mutations in 100 families, representing a prevalence of 17.1%. In total, 25 and 12 different BRCA1 and BRCA2 mutations, respectively, that were detected by DNA sequencing and 2 LGRs in BRCA1 gene were found by MLPA. Mutations c.5266dupC detected in 38%; p.Cys61Gly in 17%; c.68_69delAG, c.3700_3704del5 each in 5% and finally c.843_846del4, c.4243delG each in 4% of families represent high-frequency Slovak BRCA1 pathogenic mutations. Altogether, these five BRCA1 mutations were present in 73% of all BRCA1 positive HBOC families.
We observed that besides the familial occurrence of the cancer disease, other important clinical criterion for BRCA1 analysis is the presence of a breast cancer diagnosed around the age of 40, in association with the presence of ovarian cancer diagnosed around 50 years of age. Conversely, for BRCA2 analysis, the diagnosis of breast cancer diagnosed at older age, around age of 50, or the presence of breast cancer in association with broader spectrum of other carcinomas (prostate, colorectum, ovaria and uterus) was clinically most indicative.
In silico prediction analysis complemented with segregation analysis may represent the model of standard diagnostic protocol for interpretation of exonic missense uncertain variants. Haplotypes of BRCA1 gene may represent potential modifiers of cancer risk in the future, as a part of the concept of BRCA intra-gene modifier factors. This approach should be based on the complex genomic analysis of both genes (promoter, epigenetic, intronic, microRNA, UVs and SNP haplotypes). Finally, we conclude that the analysis of other HBOC risk genes TP53 and CHEK2*c.1100delC is not efficient in Slovak HBOC families.
This is the first comprehensive study of moleculargenetic features of HBOC syndrome in Slovak families which includes deleterious mutations, variants with uncertain clinical significance and SNP haplotypes.
